Sino Biological Launches 4RISE™ Wet-Lab Validation for AI-Designed Binders

Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the launch of its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders. The service addresses a critical bottleneck in AI-driven protein design: the need for experimental validation to confirm that computational designs actually bind to their intended targets. By combining rapid experimental turnaround, scalable screening workflows, and structured data delivery, 4RISE™ aims to support continuous design-test-learn cycles for AI-focused life sciences researchers.

At the core of the service is Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform, which enables recombinant protein synthesis in just 3 hours with expression success rates exceeding 99% in established workflows. The platform supports miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines. Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination, producing sequence-to-AI-ready binding data in as little as 3 days. Structured binding data are accessible in real time via API, enabling seamless data retrieval for downstream research and analysis.

4RISE™ offers four rapid screening services tailored to diverse research needs: Rapid Hit Discovery for binding-positive miniproteins and VHHs via crude-supernatant screening; Comparative Binder Screening for purified candidates under standardized conditions; Affinity & Kinetic Characterization for quantitative binding insights; and Specialized Binder Expression & Validation for diverse binder formats through tailored mammalian expression and binding analysis. Beyond binding, the service provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays. Sino Biological has worked with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering, with studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., noted that AI-designed molecules need reliable wet-lab evidence to demonstrate their potential and that the integrated capabilities provide high-quality data to evaluate candidates quickly. Researchers can Explore 4RISE™ High-Throughput Wet-Lab Validation Services Now!